Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

Abstract

Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts.

Journal

Title: The Lancet

Abbreviated Title: The Lancet

Publisher: Elsevier BV

ISSN (Print): 01406736

Publication date Created: October 2016

Publication date (Print): October 2016

Volume: 388

Issue: 10056

Pages: 2128-2141

Article

DOI: 10.1016/S0140-6736(16)31322-8

PubMed ID: 27609406

Copyright statement: © 2016

License:

http://www.elsevier.com/tdm/userlicense/1.0/

Product

Self URI (article page): http://linkinghub.elsevier.com/retrieve/pii/S0140673616313228